Lv3
223 积分 2021-07-14 加入
Late and Durable Minimal Residual Disease Response Predicts Favorable Outcomes in Newly Diagnosed Multiple Myeloma
1个月前
已完结
Outcomes With First‐Line PD1 Inhibitors in Extranodal NK/T‐Cell Lymphoma: A Comparative Analysis From a 755‐Patient Multicenter Cohort
1个月前
已关闭
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial
2个月前
已完结
Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation
2个月前
已完结
Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma
2个月前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
4个月前
已完结
Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis
4个月前
已完结
Bispecific antibody combination therapies in diffuse large B‐cell lymphoma
5个月前
已完结
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
6个月前
已完结
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib
8个月前
已完结
皖公网安备34019202002308
